EUVIMEDEUVIMED entdecken
Crossref

HMX3 is a critical vulnerability in MECOM-negative KMT2A::MLLT3 acute myelomonocytic leukemia

Saioa Arza-Apalategi, Branco M H Heuts, Saskia M Bergevoet, Roos Meering, Daan Gilissen, Pascal W T C Jansen, Anja Krippner-Heidenreich, Peter J M Valk, Michiel Vermeulen, Olaf Heidenreich, Torsten Haferlach, Joop H Jansen und 2 weitere

Leukemia · 2025

DOI: 10.1038/s41375-024-02485-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Leukemia, 2025. Verfasst von Saioa Arza-Apalategi und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, Laboratory of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands. Hauptthemen laut MEDLINE: Myeloid-Lymphoid Leukemia Protein, Histone-Lysine N-Methyltransferase, Leukemia, Myelomonocytic, Acute, Homeodomain Proteins. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: Stichting Kinderen Kankervrij (KiKa).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myeloid-Lymphoid Leukemia ProteinHistone-Lysine N-MethyltransferaseLeukemia, Myelomonocytic, AcuteHomeodomain ProteinsHumansMaleAdultFemaleGene Expression Regulation, LeukemicMiddle AgedAgedChildNuclear Proteins

Substanzen

Myeloid-Lymphoid Leukemia ProteinKMT2A protein, humanHistone-Lysine N-MethyltransferaseMLLT3 protein, humanHomeodomain ProteinsNuclear Proteins

Autor:innen und Institutionen

  • Department of Laboratory Medicine, Laboratory of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Department of Molecular Biology, Faculty of Science, Radboud Institute for Molecular Life Sciences, Oncode Institute, Radboud University, Nijmegen, The Netherlands.
  • Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
  • Department Hematology, Erasmus MC, Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.
  • MLL Munich Leukemia Laboratory, Munich, Germany.
  • Department of Laboratory Medicine, Laboratory of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands. Bert.vanderReijden@radboudumc.nl.

Förderung

  • Stichting Kinderen Kankervrij (KiKa)

Zitieren

APA

Arza-Apalategi, S., Heuts, B. M. H., Bergevoet, S. M., Meering, R., Gilissen, D., Jansen, P. W. T. C., Krippner-Heidenreich, A., Valk, P. J. M., Vermeulen, M., Heidenreich, O., Haferlach, T., Jansen, J. H., Martens, J. H. A., & van der Reijden, B. A. (2025). HMX3 is a critical vulnerability in MECOM-negative KMT2A::MLLT3 acute myelomonocytic leukemia. Leukemia. https://doi.org/10.1038/s41375-024-02485-3

Vancouver

Arza-Apalategi S, Heuts BMH, Bergevoet SM, Meering R, Gilissen D, Jansen PWTC, et al. HMX3 is a critical vulnerability in MECOM-negative KMT2A::MLLT3 acute myelomonocytic leukemia. Leukemia. 2025. doi:10.1038/s41375-024-02485-3

BibTeX
@article{ArzaApalategi2025,
  author = {Arza-Apalategi, Saioa and Heuts, Branco M H and Bergevoet, Saskia M and Meering, Roos and Gilissen, Daan and Jansen, Pascal W T C and Krippner-Heidenreich, Anja and Valk, Peter J M and Vermeulen, Michiel and Heidenreich, Olaf and Haferlach, Torsten and Jansen, Joop H and Martens, Joost H A and van der Reijden, Bert A},
  title = {HMX3 is a critical vulnerability in MECOM-negative KMT2A::MLLT3 acute myelomonocytic leukemia},
  journal = {Leukemia},
  year = {2025},
  doi = {10.1038/s41375-024-02485-3}
}
Kostenlos starten →